Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tohyama, Osamu, Matsui, Junji, Kodama, Kotaro, Hata-Sugi, Naoko, Kimura, Takayuki, Okamoto, Kiyoshi, Minoshima, Yukinori, Iwata, Masao, Funahashi, Yasuhiro
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177084/
https://ncbi.nlm.nih.gov/pubmed/25295214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/638747
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados